Immune Checkpoint Inhibitor-Induced Psoriasis
- 15 March 2024
- journal article
- research article
- Published by Elsevier in Dermatologic Clinics
- Vol. 42 (3) , 481-493
Abstract
No abstract availableKeywords
This publication has 109 references indexed in Scilit:
- A case of de novo psoriasis secondary to atezolizumab in a patient with hepatocellular carcinomaThe Kaohsiung Journal of Medical Sciences, 2022
- Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 TherapyJAMA Dermatology, 2022
- Psoriasis Prevalence in Adults in the United StatesJAMA Dermatology, 2021
- A case of de novo psoriasis induced by atezolizumab in a patient with advanced lung cancerJournal of Cutaneous Immunology and Allergy, 2019
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort StudyArthritis & Rheumatology, 2019
- High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanomaCancer, 2018
- Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic MelanomaJAMA Dermatology, 2016
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune DisordersJAMA Oncology, 2016
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease ProgressionJAMA Dermatology, 2015
- Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal MelanomaJAMA Dermatology, 2015